Related Experiment Video
Updated: May 10, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
The diagnosis and treatment of giant cell arteritis
Thomas Ness1, Thorsten A Bley, Wolfgang A Schmidt
1University Eye Hospital Freiburg, Germany. thomas.ness@uniklinik-freiburg.de
Insights
Giant cell arteritis (GCA) is a common vasculitis affecting older adults. Early diagnosis and treatment with corticosteroids, potentially with methotrexate or azathioprine, are crucial to prevent serious complications like vision loss.
Area of Science:
- Rheumatology
- Vasculitis Research
Background:
- Giant cell arteritis (GCA) is the most prevalent systemic vasculitis in individuals over 50.
- It impacts cranial arteries, the aorta, and peripheral arteries, with an incidence of 3.5 per 100,000 annually.
Purpose of the Study:
- To review pertinent literature, guidelines, and recommendations for Giant Cell Arteritis (GCA).
- To summarize current diagnostic and therapeutic approaches for GCA.
Main Methods:
- Selective review of relevant scientific literature.
- Inclusion of international and German guidelines and recommendations.
Main Results:
- Typical GCA symptoms include headaches, jaw claudication, scalp tenderness, visual disturbances, and systemic effects.
- Diagnosis involves lab tests (ESR, CRP), imaging (ultrasound, MRI, PET), and temporal artery biopsy.
- Corticosteroids are standard treatment; methotrexate is recommended to reduce recurrence and steroid dependence, with azathioprine as an alternative.
Conclusions:
- Untreated GCA can lead to aortic involvement and complications.
- Delayed diagnosis and treatment of GCA increase the risk of irreversible visual impairment and other severe outcomes.
Background:
Giant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100,000 per year). It affects cranial arteries, the aorta, and arteries elsewhere in the body, e.g., in the limbs.
Methods:
We selectively review the pertinent literature, including guidelines and recommendations from Germany and abroad.
Results:
The typical symptoms of new-onset GCA are bitemporal headaches, jaw claudiacation, scalp tenderness, visual disturbances, systemic symptoms such as fever and weight loss, and polymyalgia. The diagnostic assessment comprises laboratory testing (erythrocyte sedimentation rate, C-reactive protein), imaging studies (duplex sonography, high-resolution magnetic resonance imaging, positron-emission tomography), and temporal artery biopsy. The standard treatment is with corticosteroids (adverse effects: diabetes mellitus, osteoporosis, cataract, arterial hypertension). A meta-analysis of three randomized controlled trials led to a recommendation for treatment with methotrexate to lower the recurrence rate and spare steroids. Patients for whom methotrexate is contraindicated or who cannot tolerate the drug can be treated with azathioprine instead.
Conclusion:
Giant cell arteritis, if untreated, progresses to involve the aorta and its collateral branches, leading to various complications. Late diagnosis and treatment can have serious consequences, including irreversible loss of visual function.
Related Concept Videos
Aneurysm III: Interprofessional Care
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Aortic Regurgitation III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
